Lirio Expands Its Proven Behavioral Science and Agentic AI Platform to Life Sciences, Bridging the Gap Between Data and Real-World Behavior
Lirio, the first-ever behavioral science and agentic AI platform that empowers people to live their healthiest lives, announced the launch of its solution, Precision Nudging for Life Sciences, developed to help pharmaceutical and biotechnology companies deliver adaptive, behaviorally informed messaging directly to patients and caregivers across every stage of the treatment journey.
Health Technology Insights: Fractal Earns AWS Generative AI Consulting Competency
As federal regulations tighten around traditional patient outreach methods and more life sciences companies adopt direct-to-consumer models, the responsibility of patient engagement, including medication adherence, is increasingly shifting to individual brands. With its new product offering, Lirio is expanding its proven n-of-1approach to enhancing patient engagement beyond care delivery, helping life sciences teams meet the growing demand for real-world impact, including higher treatment initiation, stronger adherence, and improved patient outcomes.
“We are at an inflection point where outreach rules are becoming stricter, patients are choosing brands that make their experience easier, and payers are focusing on outcomes instead of impressions. At the same time, privacy changes and the unbundling of care are making direct, consent-based relationships essential. As life sciences organizations embrace new direct-to-patient models, AI-driven behavioral science is the critical bridge between compliant communication and value-creating patient engagements,” said Barbara Salami, former VP of Commercial Excellence and Innovation at Novo Nordisk. “It learns what each patient needs next, adapts with empathy, records every decision for auditability, and turns communication into outcomes such as faster starts, fewer drop-offs, and more confident care journeys.”
Health Technology Insights: Investors Eye AI Imaging Firms in Growing Breast Cancer Market
Powered by its unique combination of behavioral science and agentic AI, Lirio’s new Life Sciences solutions help organizations deliver deep personalization across every stage of the patient journey. Precision Nudging enables life sciences teams to:
- Boost adherence and persistence by identifying and addressing behavioral barriers that prevent patients from starting or staying on therapy.
- Enhance patient and hub support programs through automated, omnichannel nudges that guide patients and caregivers through enrollment, access, and financial assistance.
- Advance chronic care management by sustaining long-term engagement for patients managing ongoing therapies.
- Accelerate recruitment and improve retention with personalized consent and enrollment messaging that builds trust and reduces drop-off.
- Deepen HCP engagement with adaptive outreach tailored to each provider’s needs and their patients’ motivations.
Together, these capabilities help life sciences organizations better understand and move the patients they serve—translating behavioral insight into measurable clinical, operational, and financial outcomes.
“Despite record investments in technology and solutions to improve pharma marketing and hub programs, many patients still don’t start or stay on a therapy or medication,” said Amy Bucher, PhD, Chief Behavioral Officer at Lirio. “This comes down to patients’ unique mix of barriers, like not understanding what’s being prescribed, not trusting it, not being able to afford it, or struggling to make the lifestyle changes that maximize therapy outcomes. With this new offering, we’re helping life sciences teams empower their patients, utilizing best-in-class behavioral science insights to personalize their approach and give patients the best chance for success.”
Health Technology Insights: Lindus Health Names Heather Davis VP of US Clinical Operations
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
